FG
ELGX

Formula Growth’s Endologix Inc ELGX Stock Holding History

Formula Growth’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,740
Closed -$1.5M – 163
2016
Q3 		$1.5M Hold
11,740
– – 0.34% 91
2016
Q2 		$1.46M Buy
+11,740
New +$1.35M 0.36% 96

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Formula Growth's ELGX Position: Q4 2016 in Review

Formula Growth sold out of Endologix Inc (ELGX) in Q4 2016, closing a stake of 11,740 shares — an estimated $1.5M sold.

Formula Growth first reported a position in ELGX in Q2 2016 and held it in 2 quarters. The position peaked at $1.5M in Q3 2016. 140 funds tracked by Wall St. Rank hold ELGX as of Q4 2016.

  • Formula Growth reported no remaining Endologix Inc position as of Q4 2016 after selling out during the quarter.
  • Formula Growth sold 11,740 Endologix Inc shares in Q4 2016, an estimated $1.5M.
  • Formula Growth first reported a position in Endologix Inc in Q2 2016 and held it in 2 quarters.
  • Formula Growth's Endologix Inc position peaked at $1.5M in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Endologix Inc as of Q4 2016.

Based on Formula Growth's 13F filing for Q4 2016, filed 13 Feb 2017.